Axsome Therapeutics has been granted a patent for a method of treating narcolepsy with cataplexy using reboxetine. The method involves administering 8-10 mg of reboxetine daily for at least two weeks to reduce daytime sleepiness in patients experiencing frequent cataplexy attacks. GlobalData’s report on Axsome Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Axsome Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Axsome Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Axsome Therapeutics's grant share as of February 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

Treating narcolepsy with cataplexy using reboxetine

Source: United States Patent and Trademark Office (USPTO). Credit: Axsome Therapeutics Inc

A recently granted patent (Publication Number: US11883408B2) outlines a method for reducing daytime sleepiness in individuals experiencing narcolepsy with cataplexy. The method involves administering a daily dose of about 8 mg to 10 mg of reboxetine for a minimum of two weeks to individuals who have had at least 7 cataplexy attacks in the week preceding the treatment initiation. The effectiveness of the treatment is assessed by a reduction in daytime sleepiness, as measured by the Epworth Sleepiness Scale scores.

The patent further details variations in the administration of reboxetine, including dosage forms containing additional components such as polymers, binders, lubricants, diluents, and disintegrants. Different dosing schedules are also described, ranging from twice daily administration of 4 mg to morning and afternoon variations of 6 mg and 4 mg, or 5 mg and 5 mg. The method is specifically targeted at individuals diagnosed with narcolepsy with cataplexy meeting specific criteria outlined in the International Classification of Sleep Disorders, Third Edition, and who exhibit an Epworth Sleepiness Scale score exceeding 10 prior to treatment initiation.

To know more about GlobalData’s detailed insights on Axsome Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies